Nicox's ZERVIATE Receives IND Approval in China

Press Release
Nicox's ZERVIATETM Receives IND Approval in China
September 22, 2020 - release at 7:30 am Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Ocumension Therapeutics, has received approval from China's Center for Drug Evaluation of the National Medical Products Administration to carry out Phase 3 clinical trials on ZERVIATETM (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis. ZERVIATE, the first topical ocular form of cetirizine, is licensed exclusively to Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. The Phase 3 trial is expected to start in Q4 2020. Dr. José Boyer, Vice President and Head, Clinical Development at Nicox, said: "The submission of the IND in China was the result of an effective collaboration between the development teams at Ocumension and Nicox. This approval allows Ocumension to accelerate the Phase 3 program for the approval of ZERVIATE in China, and we look forward to continuing to support them in the next steps of bringing ZERVIATE to commercialisation there." The Press Release by Ocumension can be found here: https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0922/2020092200013.pdf (https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0922/2020092200013.pdf) About ZERVIATE ZERVIATETM (cetirizine ophthalmic solution), 0.24% is a novel formulation of cetirizine developed and approved for the first time for topical application in the eye for the treatment of ocular itching associated with allergic conjunctivitis. Cetirizine, the active ingredient in ZYRTEC, is a second-generation antihistamine (H1 receptor antagonist) that binds competitively to histamine receptor sites. Cetirizine, in approved oral formulations, has a well-characterized systemic efficacy and safety profile with worldwide exposure resulting from 20 years of oral use. ZERVIATE was developed by Nicox as the first and only formulation of cetirizine for topical application in the eye. ZERVIATE was launched in the United States in March 2020 by Eyevance Pharmaceuticals, Nicox's exclusive U.S. licensee, and is also licensed exclusively to Samil Pharmaceutical in South Korea and to ITROM Pharmaceutical Group in the Gulf and Arab markets. About Allergic Conjunctivitis Allergic conjunctivitis occurs when an allergic reaction causes conjunctivitis. Conjunctivitis is an inflammation of the thin layer of tissue that lines the outside of the white surface of the eye and the inner surface of the eyelids. It may affect one or both eyes. The signs and symptoms may include eye redness, excessive watering, itchy burning eyes, discharge, blurred vision and increased sensitivity to light.
About Nicox
Nicox S.A. is an ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch & Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and Southeast Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com (http://www.nicox.com).
Analyst coverage
Bryan, Garnier & Co Victor Floc'h Paris, France Cantor Fitzgerald Louise Chen New York, U.S. H.C. Wainwright & Co Yi Chen New York, U.S. Oppenheimer & Co Hartaj Singh New York, U.S.
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Contacts
Nicox Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development T [phone] [e-mail] (mailto:[e-mail])
Investors & Media United States & Europe LifeSci Advisors, LLC Mary-Ann Chang T [phone] [e-mail] (mailto:[e-mail])	Media France LifeSci Advisors, LLC Sophie Baumont M [phone] [e-mail] (mailto:[e-mail])
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2019' filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox's website (www.nicox.com (http://www.nicox.com)).
Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T [phone] F [phone]

Attachment

• EN_ZERVIATEChineseINDapproval_20200922_F (https://ml-eu.globenewswire.com/Resource/Download/031cae5c-33a9-4f89-9710-f1a9a4353b19)